MeSH Browser

MeSH Heading: Cytochrome P-450 CYP2D6
Tree Number(s): D08.244.453.005.600; D08.244.453.491.372; D08.811.682.690.708.170.010.600; D08.811.682.690.708.170.450.368; D12.776.422.220.453.010.600; D12.776.422.220.453.491.368
Unique ID: D019389
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D019389
Scope Note: A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
Entry Term(s): CYP 2D6; CYP2D6; Cytochrome P450 2D6; Debrisoquine 4-Hydroxylase; Debrisoquine 4-Monooxygenase; Debrisoquine Hydroxylase; Imipramine 2-Hydroxylase; Sparteine Monooxygenase
Registry Number: EC 1.14.14.1
Previous Indexing: Cytochrome P-450 (1975-1996); Hydroxylases (1979-1996)
Public MeSH Note: 97; DEBRISOQUINE 4-HYDROXYLASE was indexed under CYTOCHROME P-450 & HYDROXYLASES 1982-96
Online Note: use CYTOCHROME P-450 CYP2D6 (NM) to search DEBRISOQUINE 4-HYDROXYLASE 1982-96
History Note: 97; was DEBRISOQUINE 4-HYDROXYLASE (NM) 1982-96
Entry Combination: antagonists & inhibitors:Cytochrome P-450 CYP2D6 Inhibitors
Date Established: 1997/01/01
Date of Entry: 1996/06/13
Revision Date: 2016/05/27

Entry Combination: antagonists & inhibitors:Cytochrome P-450 CYP2D6 Inhibitors
Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

analysis (AN)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

deficiency (DF)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Concept UI: M0028855
Registry Number: EC 1.14.14.1
Scope Note: A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
Terms: Cytochrome P-450 CYP2D6 Preferred Term
Term UI T057804
Date01/01/1999
LexicalTag ABX
ThesaurusID NLM (1997); Sparteine Monooxygenase
Term UI T057797
Date02/13/1996
LexicalTag NON
ThesaurusID NLM (1997); Cytochrome P450 2D6
Term UI T057798
Date03/13/1996
LexicalTag NON
ThesaurusID NLM (1997); Debrisoquine 4-Monooxygenase
Term UI T057799
Date02/13/1996
LexicalTag NON
ThesaurusID NLM (1997); Imipramine 2-Hydroxylase
Term UI T057801
Date02/13/1996
LexicalTag NON
ThesaurusID NLM (1997); CYP2D6
Term UI T057802
Date02/07/1996
LexicalTag ABB
ThesaurusID NLM (1997); CYP 2D6
Term UI T057803
Date02/07/1996
LexicalTag ABB
ThesaurusID NLM (1997); Debrisoquine 4-Hydroxylase
Term UI T057796
Date02/07/1996
LexicalTag NON
ThesaurusID NLM (1997); Debrisoquine Hydroxylase
Term UI T057800
Date02/07/1996
LexicalTag NON
ThesaurusID NLM (1997)

Cytochrome P-450 CYP2D6 MeSH Descriptor Data 2023